 Home > Medical News > Latest Medical News > Catch up with Farxiga/Jardiance, Johnson & Johnson releases Phase III clinical results of hypoglycemic drug Invokana

Catch up with Farxiga/Jardiance, Johnson & Johnson releases Phase III clinical results of hypoglycemic drug Invokana

 Last Update: 2021-12-07
 Source: Internet
 Author: User

Tags

fda drug database

6 4 titanium

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

Recently, Phase 3 data released at the 2021 Virtual Science Conference of the American Heart Association (AHA) showed that Johnson & Johnson’s type 2 diabetes drug Invokana (canagliflozin) has helped improve the symptoms of heart failure in patients, regardless of whether they have Diabetes

These positive data are expected to make Invokana the newest sodium-glucose cotransporter 2 (SGLT2) inhibitor after AstraZeneca’s Farxiga (Dapagliflozin), Boehringer Ingelheim/Lilly Jardiance (Enpagliflozin), Achieve a leap from the treatment of type 2 diabetes to the treatment of heart failure

The researchers said that patients taking Invokana showed "significant improvement" in heart failure symptoms compared to placebo

A total of 476 patients were enrolled in this trial, including 285 patients with HFpEF and 191 patients with HFrEF

Due to the COVID-19 pandemic, the research team actually conducted virtual clinical trials (also known as "decentralized" or "decentralized" clinical trials)

If approved in the heart failure indication, Invokana will keep pace with similar products Farxiga and Jardiance to compete for market share

Invokana is the first SGLT2 inhibitor approved by the U.

Reference source: AHA: J&J's Invokana chases AZ's Farxiga and Lilly's Jardiance with phase 3 heart failure win

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.